Al-Sowayan Balta, Keogh Rosemary J, Abumaree Mohammed, Georgiou Harry M, Kalionis Bill
Department of Maternal-Fetal Medicine, Pregnancy Research Centre, Royal Women's Hospital, Parkville, Victoria 3052, Australia.
Department of Obstetrics and Gynaecology, Royal Women's Hospital, University of Melbourne, Parkville, Victoria 3052, Australia.
Stem Cell Investig. 2019 Feb 13;6:3. doi: 10.21037/sci.2019.01.01. eCollection 2019.
The placenta is an abundant source of mesenchymal stem/stromal cells (MSC), but our understanding of their functional properties remains limited. We previously created a placental-derived chorionic MSC (CMSC) cell line to overcome the difficulties associated with conducting extensive optimization and experimental work on primary cells. The aim of this study was to characterize the migratory behavior of the CMSC29 cell line .
Stimulators of MSC migration, including two cytokines, stromal cell-derived factor-1α (SDF-1α) and hepatocyte growth factor (HGF), and a pharmacological agent, valproic acid (VPA), were tested for their ability to stimulate CMSC29 cell migration. Assessment of cell migration was performed using the xCELLigence Real-Time Cell Analyzer (RTCA).
There was no significant increase in CMSC29 cell migration towards serum free medium with increasing concentration gradients of SDF-1α or HGF. In contrast, treating CMSC29 cells with VPA alone significantly increased their migration towards serum free medium.
Immortalized CMSC29 cells retain important properties of primary CMSC, but their migratory properties are altered. CMSC29 cells do not migrate in response to factors that reportedly stimulate primary MSC/CMSC migration. However, CMSC29 increase their migration in response to VPA treatment alone. Further studies are needed to determine the mechanism by which VPA acts alone to stimulate CMSC29 migration. Still, this study provides evidence that VPA pre-treatment may improve the benefits of cell-based therapies that employ certain MSC sub-types.
胎盘是间充质干/基质细胞（MSC）的丰富来源，但我们对其功能特性的了解仍然有限。我们之前创建了一种胎盘来源的绒毛膜间充质干细胞（CMSC）细胞系，以克服对原代细胞进行广泛优化和实验工作所面临的困难。本研究的目的是表征CMSC29细胞系的迁移行为。
测试了MSC迁移刺激物，包括两种细胞因子，即基质细胞衍生因子-1α（SDF-1α）和肝细胞生长因子（HGF），以及一种药物丙戊酸（VPA），以评估它们刺激CMSC29细胞迁移的能力。使用xCELLigence实时细胞分析仪（RTCA）对细胞迁移进行评估。
随着SDF-1α或HGF浓度梯度的增加，CMSC29细胞向无血清培养基的迁移没有显著增加。相比之下，单独用VPA处理CMSC29细胞显著增加了它们向无血清培养基的迁移。
永生化的CMSC29细胞保留了原代CMSC的重要特性，但它们的迁移特性发生了改变。CMSC29细胞不会对据报道能刺激原代MSC/CMSC迁移的因子产生迁移反应。然而，CMSC29细胞仅对VPA处理会增加其迁移。需要进一步研究来确定VPA单独作用刺激CMSC29迁移的机制。尽管如此，本研究提供了证据表明VPA预处理可能会提高采用某些MSC亚型的细胞疗法的益处。
